Nektar Therapeutics (NKTR)
1.505
-0.14
(-8.79%)
USD |
NASDAQ |
May 07, 14:59
Nektar Therapeutics Cash from Operations (Quarterly): -47.05M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -47.05M |
September 30, 2023 | -42.12M |
June 30, 2023 | -51.52M |
March 31, 2023 | -51.92M |
December 31, 2022 | -57.70M |
September 30, 2022 | -82.89M |
June 30, 2022 | -74.99M |
March 31, 2022 | -88.42M |
December 31, 2021 | -151.54M |
September 30, 2021 | -101.14M |
June 30, 2021 | -82.90M |
March 31, 2021 | -77.08M |
December 31, 2020 | -98.63M |
September 30, 2020 | -52.68M |
June 30, 2020 | -83.90M |
March 31, 2020 | -78.08M |
December 31, 2019 | -125.22M |
September 30, 2019 | -68.64M |
June 30, 2019 | -53.92M |
March 31, 2019 | -80.90M |
December 31, 2018 | -117.55M |
September 30, 2018 | -71.41M |
June 30, 2018 | 959.64M |
March 31, 2018 | -52.47M |
December 31, 2017 | -80.40M |
Date | Value |
---|---|
September 30, 2017 | 93.08M |
June 30, 2017 | -58.52M |
March 31, 2017 | -34.57M |
December 31, 2016 | -52.41M |
September 30, 2016 | -27.36M |
June 30, 2016 | -13.60M |
March 31, 2016 | -23.65M |
December 31, 2015 | -75.11M |
September 30, 2015 | -14.03M |
June 30, 2015 | -47.26M |
March 31, 2015 | 63.31M |
December 31, 2014 | -24.63M |
September 30, 2014 | -46.00M |
June 30, 2014 | -9.085M |
March 31, 2014 | -62.29M |
December 31, 2013 | 53.63M |
September 30, 2013 | -19.71M |
June 30, 2013 | -34.34M |
March 31, 2013 | -38.11M |
December 31, 2012 | -47.38M |
September 30, 2012 | -27.17M |
June 30, 2012 | -20.59M |
March 31, 2012 | -34.62M |
December 31, 2011 | -42.21M |
September 30, 2011 | -21.87M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-151.54M
Minimum
Dec 2021
-42.12M
Maximum
Sep 2023
-77.39M
Average
-77.08M
Median
Mar 2021
Cash from Operations (Quarterly) Benchmarks
Stereotaxis Inc | -2.439M |
Vanda Pharmaceuticals Inc | -3.732M |
Cara Therapeutics Inc | -17.37M |
Avid Bioservices Inc | 3.687M |
Rigel Pharmaceuticals Inc | -6.24M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 17.38M |
Cash from Financing (Quarterly) | 0.012M |
Free Cash Flow | -193.47M |
Free Cash Flow Per Share (Quarterly) | -0.2475 |
Free Cash Flow to Equity (Quarterly) | -47.28M |
Free Cash Flow to Firm (Quarterly) | -44.94M |
Free Cash Flow Yield | -67.66% |